Participants are excluded from the study if any of the following criteria apply:

Medical Conditions

Pregnancy Exclusion

1) A WOCBP who has a positive urine pregnancy test (within 72 hours) prior to treatment. If

the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will

be required.

Prior/Concomitant Therapy

2) Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an

agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX40,

CD137), and was discontinued from that treatment due to a Grade 3 or higher irAE.

3) Has received prior systemic anti-cancer therapy including investigational agents within

4 weeks (could consider shorter interval for kinase inhibitors or other short half-life drugs)

prior to treatment.

Note: Participants must have recovered from all AEs due to previous therapies to

≤ Grade 1 or baseline. Participants with ≤ Grade 2 neuropathy may be eligible.

Participants with endocrine-related AEs Grade ≤ 2 requiring treatment or hormone

replacement may be eligible.

Note: If the participant had major surgery, the participant must have recovered

adequately from the procedure and/or any complications from the surgery prior to

starting study intervention.

4) Has received prior radiotherapy within 2 weeks of start of study treatment or has had a

history of radiation pneumonitis.

Note: Participants must have recovered from all radiation-related toxicities and do not

require corticosteroids. A 1-week washout is permitted for palliative radiation (≤ 2

weeks of radiotherapy) to non-CNS disease.

5) Has received G-CSF or GM-CSF within 7 days prior to start of study treatment.

6) Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study

intervention.

Note: Examples of live vaccines include, but are not limited to, the following: measles,

mumps, rubella, chicken pox/zoster, yellow fever, rabies, Bacillus Calmette-Guérin,

and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus

vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist®) are

live attenuated vaccines and are not allowed.

7) Receipt of COVID-19 vaccine within ≤ 14 days prior to first administration of study

treatments.

Note: For 2-dose COVID-19 vaccines or COVID-19 booster, participants must wait at

least 14-days after administration prior to beginning study treatment.

8) Is currently participating in or has participated in a study of an investigational agent or has

used an investigational device within 4 weeks prior to the first dose of study treatment.

Note: Participants who have entered the follow-up phase of an investigational study

may participate as long as it has been 4 weeks after the last dose of the previous

investigational agent.

9) Has had an allogeneic tissue/stem cell/solid organ transplant.

Diagnostic assessments

10) Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in

dosing exceeding 10 mg daily of prednisone equivalent) or any other form of

immunosuppressive therapy within 7 days prior to the first dose of study drug.

11) Has a known additional malignancy that is progressing or has required active treatment

within the past 3 years.

Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of

the skin, or carcinoma in situ, excluding carcinoma in situ of bladder, that have

undergone potentially curative therapy are not excluded.

12) Has known active CNS metastases and/or carcinomatous meningitis. Participants with

previously treated brain metastases may participate provided they are radiologically stable,

i.e., without evidence of progression for at least 4 weeks by repeat imaging (note that the

repeat imaging should be performed during study screening), clinically stable and without

requirement of steroid treatment for at least 14 days prior to first dose of study treatment.

13) Has severe hypersensitivity (≥ Grade 3), known allergy or reaction to Pembrolizumab,

NC410, and/or any of their excipients.

14) Has an active autoimmune disease that has required systemic treatment in past 2 years (i.e.,

with use of disease modifying agents, corticosteroids, or immunosuppressive drugs).

Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement

therapy for adrenal or pituitary insufficiency) is not considered a form of systemic

treatment and is allowed.

15) Has a history of (non-infectious) pneumonitis / interstitial lung disease that required

steroids or has current pneumonitis / interstitial lung disease.

16) Has an active infection requiring systemic therapy.

17) Has a known history of HIV infection. No HIV testing is required unless mandated by local

health authority.

18) Has a history or current evidence of any condition, therapy, or laboratory abnormality, or

other circumstance that might confound the results of the study or interfere with the

participant's participation for the full duration of the study, such that it is not in the best

interest of the participant to participate, in the opinion of the treating investigator.

19) Has a known psychiatric or substance abuse disorder that would interfere with the

participant’s ability to cooperate with the requirements of the study.